A randomized, double-blinded, placebo controlled, parallel group, multi-center study to assess safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of intravenous doses of QAX576 in moderate persistent allergic asthmatics following inhaled corticosteroid withdrawal

Trial Profile

A randomized, double-blinded, placebo controlled, parallel group, multi-center study to assess safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of intravenous doses of QAX576 in moderate persistent allergic asthmatics following inhaled corticosteroid withdrawal

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Dectrekumab (Primary)
  • Indications Allergic asthma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 02 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top